Zai Lab Sustainability Profile
Zai Lab Limited, commonly referred to as Zai Lab, is a prominent biopharmaceutical company headquartered in China. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative therapies, focusing primarily on oncology, autoimmune diseases, and infectious diseases. With a strong operational presence in both China and the United States, Zai Lab is committed to addressing unmet medical needs through its robust pipeline of novel drug candidates. The company’s core offerings include a range of proprietary and partnered products, distinguished by their unique mechanisms of action and potential to improve patient outcomes. Zai Lab has achieved significant milestones, including successful collaborations with global pharmaceutical leaders and the launch of several key therapies in the Chinese market. Recognised for its commitment to innovation, Zai Lab continues to strengthen its position in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Zai Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zai Lab's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zai Lab's reported carbon emissions
In 2024, Zai Lab reported total carbon emissions of approximately 59,814,000 kg CO2e, with emissions distributed across various scopes: 294,000 kg CO2e (Scope 1), 4,056,000 kg CO2e (Scope 2), and a significant 55,465,000 kg CO2e (Scope 3). This represents a decrease from 2023, where total emissions were about 70,321,000 kg CO2e, comprising 15,000 kg CO2e (Scope 1), 4,664,000 kg CO2e (Scope 2), and 65,642,000 kg CO2e (Scope 3). Zai Lab's emissions data indicates a focus on Scope 3 emissions, which accounted for approximately 92% of their total emissions in 2024. The company has not set specific reduction targets under the Science Based Targets initiative (SBTi), as their near-term target commitment has been removed. However, they have made recent commitments to reduce emissions, although details on specific targets or timelines are not provided. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in China. Zai Lab's emissions data is sourced directly from their own reporting, with no cascaded data from a parent organization. The company continues to engage in climate commitments, reflecting an ongoing effort to address their carbon footprint in a significant industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 28,400 | 00,000 | 00,000 | 000,000 |
| Scope 2 | 3,536,600 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Zai Lab's Industry?
How Carbon Intensive is Zai Lab's Location?
Zai Lab's Scope 3 Categories Breakdown
Zai Lab's Scope 3 emissions, which decreased by 16% last year and decreased by approximately 21% since 2022, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 95% of Scope 3 emissions.
Top Scope 3 Categories
Zai Lab's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zai Lab has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Frequently Asked Questions
Common questions about Zai Lab's sustainability data and climate commitments